Skip to main content

A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor

Research Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

July 1, 2015

End Date

December 31, 2021
 

Administered By

Duke Cancer Institute

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

July 1, 2015

End Date

December 31, 2021